Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Drugs In Development, 2022, provides an overview of the Kaposi Sarcoma (Infectious Disease) pipeline landscape.
Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. Symptoms include patches which are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kaposi Sarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kaposi Sarcoma (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kaposi Sarcoma (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 8, 6, 1, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Kaposi Sarcoma (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kaposi Sarcoma (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kaposi Sarcoma (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kaposi Sarcoma (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kaposi Sarcoma (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kaposi Sarcoma (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Kaposi Sarcoma - Overview
Kaposi Sarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Kaposi Sarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Kaposi Sarcoma - Companies Involved in Therapeutics Development
Amgen Inc
Aphios Corp
Bristol-Myers Squibb Co
Cannabis Science Inc
Cello Therapeutics Inc
Codiak BioSciences Inc
DAE HWA Pharmaceutical Co Ltd
Eli Lilly and Co
Galephar Pharmaceutical Research Inc
Genexine Inc
Kang Litai Pharmaceutical Co Ltd
LATITUDE Pharmaceuticals Inc
LipoSeuticals Inc
Macrophage Therapeutics Inc
Merck & Co Inc
Merck KGaA
Nammi Therapeutics Inc
Ono Pharmaceutical Co Ltd
Philogen SpA
Sanofi
Seven and Eight Biopharmaceuticals Corp
Statera Biopharma Inc
Tumorend LLC
VasGene Therapeutics Inc
Kaposi Sarcoma - Drug Profiles
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
BDB-001 - Drug Profile
Product Description
Mechanism Of Action
bifikafusp alfa + onfekafusp alfa - Drug Profile
Product Description
Mechanism Of Action
bintrafusp alfa - Drug Profile
Product Description
Mechanism Of Action
CDK-003 - Drug Profile
Product Description
Mechanism Of Action
CE-003 - Drug Profile
Product Description
Mechanism Of Action
CM-101 - Drug Profile
Product Description
Mechanism Of Action
CSTATI-1 - Drug Profile
Product Description
Mechanism Of Action
doxorubicin - Drug Profile
Product Description
Mechanism Of Action
efineptakin alfa - Drug Profile
Product Description
Mechanism Of Action
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
KLT-1101 - Drug Profile
Product Description
Mechanism Of Action
M-9241 - Drug Profile
Product Description
Mechanism Of Action
metenkefalin - Drug Profile
Product Description
Mechanism Of Action
nivolumab - Drug Profile
Product Description
Mechanism Of Action
NTI-1A - Drug Profile
Product Description
Mechanism Of Action
paclitaxel - Drug Profile
Product Description
Mechanism Of Action
paclitaxel - Drug Profile
Product Description
Mechanism Of Action
paclitaxel - Drug Profile
Product Description
Mechanism Of Action
paclitaxel - Drug Profile
Product Description
Mechanism Of Action
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
SAR-442720 - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to Inhibit HAUSP for Lymphoma and Kaposi Sarcoma - Drug Profile
Product Description
Mechanism Of Action
talimogene laherparepvec - Drug Profile
Product Description
Mechanism Of Action
Vas-01 - Drug Profile
Product Description
Mechanism Of Action
Kaposi Sarcoma - Dormant Projects
Kaposi Sarcoma - Discontinued Products
Kaposi Sarcoma - Product Development Milestones
Featured News & Press Releases
Apr 11, 2022: Treatment with nivolumab and low-dose ipilimumab is effective and tolerable in patients with previously treated progressive classical kaposi sarcoma
Jul 26, 2021: NeoImmuneTech receives U.S. FDA IND clearance for phase 1 study of NT-I7 (efineptakin alfa) for the treatment of Kaposi Sarcoma in patients with or without HIV infection
Apr 10, 2021: Codiak presents data at AACR 2021 demonstrating potential of engineered exosomes to enhance the therapeutic index of well-validated cancer immunotherapy pathways
Dec 30, 2020: Codiak reports positive initial phase 1 results for exoIL-12 demonstrating tolerability and absence of systemic IL-12 exposure in healthy volunteers
Dec 21, 2020: New publication in Molecular Cancer Therapeutics highlights data from preclinical development of exoIL-12 for the treatment of cancer
Nov 09, 2020: Codiak presents preclinical data at SITC 2020 demonstrating potential of engEx engineered exosomes to stimulate targeted, integrated anti-tumor immunity
Nov 07, 2017: For cancer patients with HIV, immunotherapy appears safe
May 26, 2016: $1.8 Million Fast-Track NIH SBIR Grant for Manocept Immunotherapeutics Evaluation in Kaposi’s Sarcoma Awarded to Navidea
May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update
Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposi’s Sarcoma
Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi’s Sarcoma and Tumor Associated Macrophages
Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I
Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma
Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Kaposi Sarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Kaposi Sarcoma - Dormant Projects, 2022
Kaposi Sarcoma - Dormant Projects, 2022 (Contd..1)
Kaposi Sarcoma - Discontinued Products, 2022
List of Figures
Number of Products under Development for Kaposi Sarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
